Method for recovering cyclosporine crude product from production waste liquid and cyclosporine crude product
By employing steps such as vacuum concentration, freeze crystallization, and rinsing centrifugation, combined with solvents of different polarities, the problems of low recovery rate and low purity of the target product in cyclosporine production waste liquid have been solved, achieving efficient and economical cyclosporine recovery suitable for industrial production.
Patent Information
- Application Number
- CN202610356206.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-23
- Publication Date
- 2026-05-19
AI Technical Summary
In the existing technology, the waste liquid generated during the production of cyclosporine contains a large amount of the target product. However, due to the complexity of the composition and the difficulty in removing impurities, it leads to resource waste and high production costs. Existing processes are difficult to efficiently recover cyclosporine.
By employing steps such as vacuum concentration, freeze crystallization, and rinsing centrifugation, combined with the use of solvents of different polarities, cyclosporine is separated through multiple crystallizations and rinsing. Taking advantage of the low solubility and solubility characteristics of cyclosporine in acetone, the target product is efficiently separated and purified.
It achieves a cyclosporine recovery rate of 45%-65% from waste liquid, increases purity to over 90%, significantly reduces production costs, and is suitable for industrial applications.
Smart Images

Figure CN122060036A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of chemical separation engineering technology, and in particular to a method for recovering crude cyclosporine from production waste liquid and crude cyclosporine. Background Technology
[0002] Cyclosporine (also known as cyclosporine A) is a cyclic polypeptide compound composed of 11 amino acids, isolated from fungal metabolites. As a potent immunosuppressant, cyclosporine has been a landmark achievement in clinical medicine. It reversibly blocks resting lymphocytes in the G0 or G1 phase of the cell cycle by specifically inhibiting the activation and proliferation of T lymphocytes and blocking the gene transcription and release of lymphokines such as interleukin-2 (IL-2). This drug can effectively suppress various cell-mediated immune responses, including allogeneic immunity, delayed-onset hypersensitivity, experimental allergic encephalomyelitis, Freund's adjuvant arthritis, and graft-versus-host disease (GVHD). Due to its unique mechanism of action—specific and reversible action on lymphocytes without affecting hematopoietic and phagocytic cell function—cyclosporine has become a first-line basic immunosuppressant for preventing rejection and graft-versus-host disease after solid organ transplantation (such as kidney, liver, and heart) and bone marrow transplantation. In addition, this drug is also widely used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and nephrotic syndrome.
[0003] With the widespread clinical application of cyclosporine, its market demand continues to grow, placing higher demands on the control of its purity and production costs. Currently, industrial production of cyclosporine mainly employs microbial fermentation, followed by a series of refining and purification processes to obtain high-purity products. A typical refining process includes key steps such as fermentation broth pretreatment, extraction, chromatographic separation, and crystallization. Among these, crystallization and chromatography are the core steps determining the purity of the final product. However, these steps generate a large amount of waste streams: namely, crystallization centrifugation waste liquid and chromatographic elution waste liquid. These waste liquids contain a considerable amount of the target product, cyclosporine. Statistics show that the total amount of cyclosporine lost in the waste liquid typically accounts for 25% to 40% of the total cyclosporine before entering this step. This means that during the purification process, one-quarter to nearly half of the product enters the waste liquid due to the inability to effectively retain it, resulting in a huge waste of resources.
[0004] From a compositional perspective, after preliminary extraction, the normalized cyclosporine content of the fermentation end product typically reaches around 89%, making it relatively easy to purify subsequently. However, the waste liquid discharged from the crystallization or chromatography stage is extremely complex, with a normalized cyclosporine content of only around 65%, far below the normal process level. The waste liquid contains a large number of difficult-to-remove impurities, mainly including: residual bio-oil esters from the fermentation process, miscellaneous proteins released after cell disruption, additives used for process adjustment, and a series of fermentation byproducts with structures very similar to cyclosporine A, such as cyclosporine B, cyclosporine C, and cyclosporine G homologues. These homologues have similar chemical properties to the target product, making separation extremely difficult, thus preventing the waste liquid from being recycled through conventional reuse or simple treatment as in the main process. Currently, most of this waste liquid is treated as industrial waste for disposal, which not only significantly increases raw material consumption and production costs but also puts pressure on the environment.
[0005] Therefore, developing an economical, efficient, and environmentally friendly new recycling process for the waste liquid generated during the cyclosporine extraction process, which is rich in the target product but has a complex composition and is difficult to treat, is of great practical significance and economic value in order to achieve resource reuse and reduce production costs. Summary of the Invention
[0006] In order to provide a separation method for cyclosporine production with high yield, high purity, low cost and simple process, this application provides a method for recovering crude cyclosporine from production waste liquid and crude cyclosporine.
[0007] In a first aspect, this application provides a method for recovering crude cyclosporine from production waste liquid, comprising the following preparation steps:
[0008] S1, the waste liquid is concentrated under reduced pressure into a colloidal concentrate, acetone is added and mixed evenly to form a mixture, and then the mixture is placed in a freezing environment to crystallize;
[0009] S2, centrifuge the crystals obtained in step S1, and wash and centrifuge them with a non-polar organic solvent and / or a moderately polar organic solvent to obtain primary crystals;
[0010] S3, dissolve the primary crystallizer in a moderately polar organic solvent, then concentrate it under reduced pressure to form a colloidal concentrate, add acetone and stir well, then place it in a frozen environment to crystallize;
[0011] S4. Centrifuge the crystals obtained in S3 and wash them with a non-polar organic solvent and / or a moderately polar organic solvent while centrifuging to obtain crude cyclosporine.
[0012] Furthermore, the waste liquid includes chromatography waste liquid or centrifugation waste liquid.
[0013] Furthermore, in steps S1 and S3, the amount of acetone used is 0.5-2 times the volume of the concentrated liquid.
[0014] Furthermore, the freezing environment in steps S1 and S3 is -30 to -5 ℃, and the temperature is maintained in the freezing environment for 4 to 25 hours.
[0015] Furthermore, in step S2, the solvent used for rinsing is a mixture of non-polar organic solvent and moderately polar organic solvent in a volume ratio of 0.5-2:1.
[0016] Furthermore, in step S4, the solvent used for rinsing is a non-polar organic solvent.
[0017] Furthermore, the non-polar organic solvent is any one or a combination of petroleum ether, n-hexane, n-heptane, and cyclohexane; the moderately polar organic solvent is any one or a combination of dichloromethane, ethyl acetate, chloroform, and acetonitrile.
[0018] Furthermore, the HPLC purity of cyclosporine in the waste liquid was 60-80%.
[0019] Secondly, this application provides a crude cyclosporine product obtained using the method described in this application.
[0020] Furthermore, the HPLC purity of crude cyclosporine is greater than 90%.
[0021] Beneficial Effects: 1. A method for recovering crude cyclosporine from production waste liquid, comprising the following steps: waste liquid concentration; primary crystallization; secondary crystallization and drying. This invention's method for recovering crude cyclosporine from production waste liquid can recover 45%-65% of the cyclosporine from the waste liquid, making it very economical and practical, suitable for industrial production. This invention achieves the recovery of cyclosporine from waste liquid, and the recovered crude cyclosporine can be used in the refining production of cyclosporine, which can greatly reduce the production cost of cyclosporine. Furthermore, the process route is simple, the material consumption is low, and the emissions of waste are minimal, meeting the needs of economic, environmental, and social progress.
[0022] 2. Furthermore, this application employs vacuum concentration to transform the waste liquid containing a large amount of bio-oil and protein into a colloidal state. Acetone is then added, utilizing its low solubility for cyclosporine to crystallize and separate the target product from the concentrate, while simultaneously rejecting some impurities. Secondly, in the first centrifugal rinsing, a mixture of non-polar and moderately polar organic solvents is used for broad-spectrum impurity removal. The second rinsing uses a non-polar organic solvent to specifically remove some non-polar impurities. These two rinsing processes constitute a layered cleaning process from the surface to the core. Simultaneously, the "dissolve-recrystallize" cycle not only amplifies the separation effect between structurally similar homologues (such as cyclosporine B and C) and the target product, but also ensures orderly crystal growth through low-temperature settling, while high-speed centrifugation forcibly removes impurities adsorbed from the mother liquor. This alternating enhancement of physicochemical methods, the polarity gradient design of the rinsing solution, and the crystallization-centrifugation cycle create a synergistic deep purification effect, causing the product purity to jump from approximately 65% to over 90%.
[0023] 3. This application utilizes the solubility characteristics of cyclosporine in acetone (cyclosporine has low solubility in cold acetone and is prone to crystallization, while cyclosporine can be dissolved in hot acetone), and selects the preferred solvents for dissolution and rinsing; employs a simple process to achieve a more thorough separation of byproducts from cyclosporine, thereby obtaining cyclosporine with high HPLC purity. Attached Figure Description
[0024] Figure 1 This is a flowchart of the process of the method in Embodiment 1 of the present invention;
[0025] Figure 2 This is a liquid chromatogram of the centrifuged waste liquid from Example 1 of the present invention;
[0026] Figure 3 This is a liquid chromatogram of crude cyclosporine obtained by the method in Example 1 of this invention. Detailed Implementation
[0027] To make the technical solution of the present invention clearer, the present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.
[0028] Example 1: A method for recovering crude cyclosporine from production waste liquid (recovering crude cyclosporine from centrifuged waste liquid), the process flow is as follows: Figure 1 The process includes the following steps:
[0029] S1, take a batch of centrifuged waste liquid (HPLC purity 66%, HPLC chromatogram shown in [reference]). Figure 2 The waste liquid was concentrated under reduced pressure until it became colloidal. Then, 0.7 times the volume of the concentrated liquid was added and stirred until it was evenly mixed. The mixture was then placed in a -10°C cold storage and allowed to stand for crystallization for 16 hours.
[0030] S2, Take the blocky crystals obtained in step S1 out of the cold storage, stir the blocky crystals evenly with a shovel, and pour about 50L of crystals into a centrifuge (centrifuge drum 0.8m, speed 1500r / min); turn on the centrifuge and centrifuge for 5min, then rinse with a mixture of petroleum ether and ethyl acetate (petroleum ether: ethyl acetate = 9:1, 30L) while centrifuging for 10min to obtain the primary crystals.
[0031] S3, the primary crystallizer is dissolved in ethyl acetate, the solution is concentrated under reduced pressure until the waste liquid is colloidal, 0.6 times the volume of the concentrated liquid is added in acetone and stirred until well mixed, the mixture is placed in a -10℃ cold storage and allowed to stand for crystallization for 16 hours.
[0032] S4. Remove the blocky crystals obtained in S3 from the cold storage, stir them evenly with a spatula, and pour about 100L of the crystals into a centrifuge (centrifuge drum 0.8m, speed 1500r / min); centrifuge for 5min, then rinse with 60L of petroleum ether while centrifuging for 10min to obtain crude cyclosporine (HPLC purity 91%, HPLC chromatogram shown in [reference needed]). Figure 3 ).
[0033] Example 2, a method for recovering crude cyclosporine from production waste liquid (recovering crude cyclosporine from chromatography waste liquid), comprising the following processing steps:
[0034] S1. Take a batch of chromatography waste liquid and concentrate it under reduced pressure until the waste liquid is in colloidal state. Add 0.6 times the volume of the concentrated liquid and stir to mix evenly. Place the mixture in a -10℃ cold storage and let it stand for crystallization for 16 hours.
[0035] S2. Take the blocky crystals obtained in step S1 out of the cold storage, stir the blocky crystals evenly with a shovel, and pour about 100L of crystals into a centrifuge (centrifuge drum 0.8m, speed 1500r / min); turn on the centrifuge and centrifuge for 5min, then rinse with 60L of petroleum ether while centrifuging for 10min to obtain the first crystals.
[0036] S3, the primary crystallizer is dissolved in ethyl acetate, the solution is concentrated under reduced pressure until the waste liquid is colloidal, 0.6 times the volume of the concentrated liquid is added in acetone and stirred until well mixed, the mixture is placed in a -10℃ cold storage and allowed to stand for crystallization for 16 hours.
[0037] S4. Take the blocky crystals obtained in S3 out of the cold storage, stir the blocky crystals evenly with a shovel, and pour about 100L of crystals into a centrifuge (centrifuge drum 0.8m, speed 1500r / min); turn on the centrifuge and centrifuge for 5min, then rinse with 40L of petroleum ether while centrifuging for 10min to obtain crude cyclosporine.
[0038] Example 3, a method for recovering crude cyclosporine from production waste liquid (from a combined solution of centrifugal waste liquid and chromatography waste liquid), includes the following processing steps:
[0039] S1. Take a batch of centrifugal waste liquid and chromatographic waste liquid combined liquid and concentrate under reduced pressure until the waste liquid is in colloidal state. Add 0.7 times the volume of the concentrated liquid and stir to mix evenly. Place the mixture in a -10℃ cold storage and let it stand for crystallization for 16 hours.
[0040] S2, Remove the lumpy crystals obtained in step S1 from the cold storage, stir them evenly with a spatula, and pour about 50L of the crystals into a centrifuge (centrifuge drum 0.8m, speed 1500r / min); centrifuge for 10min, remove the centrifuged solid and place it in a stainless steel container, add 30L of petroleum ether to the stainless steel container, and stir evenly. Pour the stirred material into a centrifuge and centrifuge for 5min, then wash with a petroleum ether-ethyl acetate mixture (petroleum ether:ethyl acetate = 9:1, 60L) while centrifuging for 10min to obtain the primary crystals.
[0041] S3, the primary crystallizer is dissolved in ethyl acetate, the solution is concentrated under reduced pressure until the waste liquid is colloidal, 0.6 times the volume of the concentrated liquid is added in acetone and stirred until well mixed, the mixture is placed in a -10℃ cold storage and allowed to stand for crystallization for 16 hours.
[0042] S4. Take the blocky crystals obtained in S3 out of the cold storage, stir the blocky crystals evenly with a shovel, and pour about 100L of crystals into a centrifuge (centrifuge drum 0.8m, speed 1500r / min); turn on the centrifuge and centrifuge for 5min, then rinse with 60L of petroleum ether while centrifuging for 10min to obtain crude cyclosporine.
[0043] Example 4, a method for recovering crude cyclosporine from production waste liquid, differs from Example 1 in that the petroleum ether in step S4 is replaced in equal amounts with a mixture of petroleum ether and ethyl acetate (9:1).
[0044] Example 5, a method for recovering crude cyclosporine from production waste liquid, differs from Example 1 in that the petroleum ether-ethyl acetate mixture in S2 is replaced with an equal amount of petroleum ether.
[0045] Example 6, a method for recovering crude cyclosporine from production waste liquid, differs from Example 1 in that the petroleum ether-ethyl acetate mixture in step S2 is replaced with petroleum ether, and the petroleum ether in step S4 is replaced with an equal amount of the petroleum ether-ethyl acetate mixture.
[0046] Comparative Example 1, a method for recovering crude cyclosporine from production waste liquid, differs from Example 1 in that acetone in steps S1 and S3 is replaced with an equal amount of diethyl ether.
[0047] HPLC detection:
[0048] The test results of the examples and comparative examples are shown in Table 1.
[0049] Table 1. List of test results for examples and comparative examples.
[0050]
[0051] The yield of crude cyclosporine is calculated as follows: (Crude cyclosporine * Crude cyclosporine weight content) / (Waste liquid volume * Waste liquid potency) * 100%.
[0052] As can be seen from Table 1, the content of a large number of unknown impurities in the cyclosporine waste liquid in Example 1 was significantly reduced. Among them, the relative peak area (i.e., HPLC content) of unknown impurity 1 decreased from 5.67% to 0.1%; the content of cyclosporine increased from 66.34% to 91.32%; the content of the main impurity cyclosporine B decreased from 9.98% to 3.21%; in addition, the content of cyclosporine C and dihydrocyclosporine did not decrease significantly and need to be removed by other processes, which are not covered by this invention patent.
[0053] The chromatographic data of the centrifuged waste liquid and crude cyclosporine from Example 1 are shown in Table 2 (corresponding to...). Figure 2 ) and Table 3 (corresponding) Figure 3 ).
[0054] Table 2, a list of chromatographic data of the liquid chromatogram of the centrifuged waste liquid in Example 1.
[0055]
[0056] Table 3 lists the chromatographic data of the crude cyclosporine obtained by the method in Example 1.
[0057]
[0058] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these modifications and improvements all fall within the scope of protection of the present invention. Therefore, the scope of protection of this patent should be determined by the appended claims.
Claims
1. A method for recovering crude cyclosporine from production wastewater, characterized in that, The preparation steps include the following: S1, the waste liquid is concentrated under reduced pressure into a colloidal concentrate, acetone is added and mixed evenly to form a mixture, and then the mixture is placed in a freezing environment to crystallize; S2, centrifuge the crystals obtained in step S1, and wash and centrifuge them with a non-polar organic solvent and / or a moderately polar organic solvent to obtain primary crystals; S3, dissolve the primary crystallizer in a moderately polar organic solvent, then concentrate it under reduced pressure to form a colloidal concentrate, add acetone and stir well, then place it in a frozen environment to crystallize; S4. Centrifuge the crystals obtained in S3 and wash them with a non-polar organic solvent and / or a moderately polar organic solvent while centrifuging to obtain crude cyclosporine.
2. The method for recovering crude cyclosporine from production waste liquid according to claim 1, characterized in that, The waste liquid includes chromatography waste liquid or centrifugation waste liquid.
3. A method for recovering crude cyclosporine from production waste liquid according to claim 1 or 2, characterized in that, In steps S1 and S3, the amount of acetone used is 0.5-2 times the volume of the concentrated liquid.
4. The method for recovering crude cyclosporine from production waste liquid according to claim 3, characterized in that, The freezing environment in steps S1 and S3 is -30 to -5 ℃, and the freezing time is 4 to 25 hours.
5. A method for recovering crude cyclosporine from production waste liquid according to any one of claims 1-2, 4, characterized in that, In step S2, the solvent used for rinsing is a mixture of non-polar organic solvent and moderately polar organic solvent in a volume ratio of 0.5-2:
1.
6. The method for recovering crude cyclosporine from production waste liquid according to claim 5, characterized in that, In step S4, the solvent used for rinsing is a non-polar organic solvent.
7. A method for recovering crude cyclosporine from production waste liquid according to any one of claims 1-2, 4, and 6, characterized in that, The non-polar organic solvent is any one or a combination of petroleum ether, n-hexane, n-heptane, and cyclohexane; the moderately polar organic solvent is any one or a combination of dichloromethane, ethyl acetate, chloroform, and acetonitrile.
8. The method for recovering crude cyclosporine from production waste liquid according to claim 7, characterized in that, The HPLC purity of cyclosporine in the waste liquid is 60-80%.
9. A crude cyclosporine product obtained by the method according to any one of claims 1-8.
10. The crude cyclosporine according to claim 9, characterized in that, Its HPLC purity is greater than 90%.
